707 related articles for article (PubMed ID: 30757937)
1. SGLT2 inhibitors and cardioprotection: a matter of debate and multiple hypotheses.
Filippatos TD; Liontos A; Papakitsou I; Elisaf MS
Postgrad Med; 2019 Mar; 131(2):82-88. PubMed ID: 30757937
[TBL] [Abstract][Full Text] [Related]
2. Cardiac ischemia-reperfusion injury under insulin-resistant conditions: SGLT1 but not SGLT2 plays a compensatory protective role in diet-induced obesity.
Yoshii A; Nagoshi T; Kashiwagi Y; Kimura H; Tanaka Y; Oi Y; Ito K; Yoshino T; Tanaka TD; Yoshimura M
Cardiovasc Diabetol; 2019 Jul; 18(1):85. PubMed ID: 31262297
[TBL] [Abstract][Full Text] [Related]
3. Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na
Uthman L; Baartscheer A; Bleijlevens B; Schumacher CA; Fiolet JWT; Koeman A; Jancev M; Hollmann MW; Weber NC; Coronel R; Zuurbier CJ
Diabetologia; 2018 Mar; 61(3):722-726. PubMed ID: 29197997
[TBL] [Abstract][Full Text] [Related]
4. A SGLT2 inhibitor dapagliflozin suppresses prolonged ventricular-repolarization through augmentation of mitochondrial function in insulin-resistant metabolic syndrome rats.
Durak A; Olgar Y; Degirmenci S; Akkus E; Tuncay E; Turan B
Cardiovasc Diabetol; 2018 Nov; 17(1):144. PubMed ID: 30447687
[TBL] [Abstract][Full Text] [Related]
5. A role for tubular Na
Onishi A; Fu Y; Patel R; Darshi M; Crespo-Masip M; Huang W; Song P; Freeman B; Kim YC; Soleimani M; Sharma K; Thomson SC; Vallon V
Am J Physiol Renal Physiol; 2020 Oct; 319(4):F712-F728. PubMed ID: 32893663
[TBL] [Abstract][Full Text] [Related]
6. Empagliflozin protects heart from inflammation and energy depletion via AMPK activation.
Koyani CN; Plastira I; Sourij H; Hallström S; Schmidt A; Rainer PP; Bugger H; Frank S; Malle E; von Lewinski D
Pharmacol Res; 2020 Aug; 158():104870. PubMed ID: 32434052
[TBL] [Abstract][Full Text] [Related]
7. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review.
Verma S; McMurray JJV
Diabetologia; 2018 Oct; 61(10):2108-2117. PubMed ID: 30132036
[TBL] [Abstract][Full Text] [Related]
8. Sympatholytic Mechanisms for the Beneficial Cardiovascular Effects of SGLT2 Inhibitors: A Research Hypothesis for Dapagliflozin's Effects in the Adrenal Gland.
Lymperopoulos A; Borges JI; Cora N; Sizova A
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299304
[TBL] [Abstract][Full Text] [Related]
9. SGLT2 Inhibitors and the Diabetic Kidney.
Fioretto P; Zambon A; Rossato M; Busetto L; Vettor R
Diabetes Care; 2016 Aug; 39 Suppl 2():S165-71. PubMed ID: 27440829
[TBL] [Abstract][Full Text] [Related]
10. Load-independent effects of empagliflozin contribute to improved cardiac function in experimental heart failure with reduced ejection fraction.
Connelly KA; Zhang Y; Desjardins JF; Nghiem L; Visram A; Batchu SN; Yerra VG; Kabir G; Thai K; Advani A; Gilbert RE
Cardiovasc Diabetol; 2020 Feb; 19(1):13. PubMed ID: 32035482
[TBL] [Abstract][Full Text] [Related]
11. Mechanistic evaluation of the effect of sodium-dependent glucose transporter 2 inhibitors on delayed glucose absorption in patients with type 2 diabetes mellitus using a quantitative systems pharmacology model of human systemic glucose dynamics.
Mori-Anai K; Tashima Y; Nakada T; Nakamaru Y; Takahata T; Saito R
Biopharm Drug Dispos; 2020 Nov; 41(8-9):352-366. PubMed ID: 33085977
[TBL] [Abstract][Full Text] [Related]
12. Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury.
Aroor AR; Das NA; Carpenter AJ; Habibi J; Jia G; Ramirez-Perez FI; Martinez-Lemus L; Manrique-Acevedo CM; Hayden MR; Duta C; Nistala R; Mayoux E; Padilla J; Chandrasekar B; DeMarco VG
Cardiovasc Diabetol; 2018 Jul; 17(1):108. PubMed ID: 30060748
[TBL] [Abstract][Full Text] [Related]
13. Cardioprotection conferred by sodium-glucose cotransporter 2 inhibitors: a renal proximal tubule perspective.
Silva Dos Santos D; Polidoro JZ; Borges-Júnior FA; Girardi ACC
Am J Physiol Cell Physiol; 2020 Feb; 318(2):C328-C336. PubMed ID: 31721613
[TBL] [Abstract][Full Text] [Related]
14. Empagliflozin Ammeliorates High Glucose Induced-Cardiac Dysfuntion in Human iPSC-Derived Cardiomyocytes.
Ng KM; Lau YM; Dhandhania V; Cai ZJ; Lee YK; Lai WH; Tse HF; Siu CW
Sci Rep; 2018 Oct; 8(1):14872. PubMed ID: 30291295
[TBL] [Abstract][Full Text] [Related]
15. Potential Mechanisms of Sodium-Glucose Co-Transporter 2 Inhibitor-Related Cardiovascular Benefits.
Verma S
Am J Cardiol; 2019 Dec; 124 Suppl 1():S36-S44. PubMed ID: 31741439
[TBL] [Abstract][Full Text] [Related]
16. Antihypertensive and Renal Mechanisms of SGLT2 (Sodium-Glucose Linked Transporter 2) Inhibitors.
Wilcox CS
Hypertension; 2020 Apr; 75(4):894-901. PubMed ID: 32114848
[TBL] [Abstract][Full Text] [Related]
17. Sodium-Glucose linked transporter 2 (SGLT2) inhibitors--fighting diabetes from a new perspective.
Angelopoulos TP; Doupis J
Adv Ther; 2014 Jun; 31(6):579-91. PubMed ID: 24972995
[TBL] [Abstract][Full Text] [Related]
18. Off-target effects of sodium-glucose co-transporter 2 blockers: empagliflozin does not inhibit Na+/H+ exchanger-1 or lower [Na+]i in the heart.
Chung YJ; Park KC; Tokar S; Eykyn TR; Fuller W; Pavlovic D; Swietach P; Shattock MJ
Cardiovasc Res; 2021 Dec; 117(14):2794-2806. PubMed ID: 33135077
[TBL] [Abstract][Full Text] [Related]
19. Clinical implications of current cardiovascular outcome trials with sodium glucose cotransporter-2 (SGLT2) inhibitors.
Lim S; Eckel RH; Koh KK
Atherosclerosis; 2018 May; 272():33-40. PubMed ID: 29547706
[TBL] [Abstract][Full Text] [Related]
20. Model-Based Evaluation of Proximal Sodium Reabsorption Through SGLT2 in Health and Diabetes and the Effect of Inhibition With Canagliflozin.
Brady JA; Hallow KM
J Clin Pharmacol; 2018 Mar; 58(3):377-385. PubMed ID: 29144539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]